Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

UbcH10 expression in human lymphomas.

Troncone G, Guerriero E, Pallante P, Berlingieri MT, Ferraro A, Del Vecchio L, Gorrese M, Mariotti E, Iaccarino A, Palmieri EA, Zeppa P, Palombini L, Fusco A.

Histopathology. 2009 May;54(6):731-40. doi: 10.1111/j.1365-2559.2009.03296.x. Erratum in: Histopathology. 2009 Jun;54(7):918. Pallante, Pierloronzo [corrected to Pallante, Pierlorenzo].

PMID:
19438748
2.

Knockdown of ubiquitin-conjugating enzyme E2C/UbcH10 expression by RNA interference inhibits glioma cell proliferation and enhances cell apoptosis in vitro.

Jiang L, Bao Y, Luo C, Hu G, Huang C, Ding X, Sun K, Lu Y.

J Cancer Res Clin Oncol. 2010 Feb;136(2):211-7. doi: 10.1007/s00432-009-0651-z. Epub 2009 Aug 6.

PMID:
19657671
3.

Association of clinicopathological features with UbcH10 expression in colorectal cancer.

Chen S, Chen Y, Hu C, Jing H, Cao Y, Liu X.

J Cancer Res Clin Oncol. 2010 Mar;136(3):419-26. doi: 10.1007/s00432-009-0672-7. Epub 2009 Sep 25.

PMID:
19779934
4.

UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas.

Berlingieri MT, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G, Ferraro A, Leone V, Sboner A, Barbareschi M, Ferro A, Troncone G, Fusco A.

Oncogene. 2007 Mar 29;26(14):2136-40. Epub 2006 Oct 2.

PMID:
17016443
5.

UbcH10 is overexpressed in malignant breast carcinomas.

Berlingieri MT, Pallante P, Sboner A, Barbareschi M, Bianco M, Ferraro A, Mansueto G, Borbone E, Guerriero E, Troncone G, Fusco A.

Eur J Cancer. 2007 Dec;43(18):2729-35. Epub 2007 Oct 22.

PMID:
17933517
6.

Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors.

Jiang L, Huang CG, Lu YC, Luo C, Hu GH, Liu HM, Chen JX, Han HX.

Brain Res. 2008 Mar 27;1201:161-6. doi: 10.1016/j.brainres.2008.01.037. Epub 2008 Jan 26.

PMID:
18331723
7.

UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status.

Pallante P, Malapelle U, Berlingieri MT, Bellevicine C, Sepe R, Federico A, Rocco D, Galgani M, Chiariotti L, Sanchez-Cespedes M, Fusco A, Troncone G.

Eur J Cancer. 2013 Mar;49(5):1117-26. doi: 10.1016/j.ejca.2012.09.033. Epub 2012 Oct 24.

PMID:
23102841
8.

RNA interference-mediated silencing of UBCH10 gene inhibits colorectal cancer cell growth in vitro and in vivo.

Chen SM, Jiang CY, Wu JY, Liu B, Chen YJ, Hu CJ, Liu XX.

Clin Exp Pharmacol Physiol. 2010 May;37(5-6):525-9. doi: 10.1111/j.1440-1681.2009.05348.x.

PMID:
20529090
9.

Clinicopathological relevance of UbcH10 in breast cancer.

Fujita T, Ikeda H, Kawasaki K, Taira N, Ogasawara Y, Nakagawara A, Doihara H.

Cancer Sci. 2009 Feb;100(2):238-48. doi: 10.1111/j.1349-7006.2008.01026.x.

10.

UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme.

Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A.

Cancer Res. 2003 Jul 15;63(14):4167-73.

11.

Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation.

van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM.

J Cell Biol. 2010 Jan 11;188(1):83-100. doi: 10.1083/jcb.200906147.

12.

Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymphomas.

Kovalevska LM, Yurchenko OV, Shlapatska LM, Berdova GG, Mikhalap SV, Van Lint J, Sidorenko SP.

Exp Oncol. 2006 Sep;28(3):225-30.

PMID:
17080017
13.

Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas.

Drakos E, Rassidakis GZ, Leventaki V, Guo W, Medeiros LJ, Nagarajan L.

Hum Pathol. 2007 Mar;38(3):500-7.

PMID:
17303500
14.

UbcH10 expression on thyroid fine-needle aspirates.

Guerriero E, Ferraro A, Desiderio D, Pallante P, Berlingieri MT, Iaccarino A, Palmieri E, Palombini L, Fusco A, Troncone G.

Cancer Cytopathol. 2010 Jun 25;118(3):157-65. doi: 10.1002/cncy.20046.

15.

Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin.

Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, Hofmann F, Deveraux QL, Hampton GM.

Oncogene. 2004 Aug 26;23(39):6621-9.

PMID:
15208666
16.

UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas.

Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, Caleo A, Migliaccio I, Decaussin-Petrucci M, Santoro M, Palombini L, Fusco A.

Br J Cancer. 2005 Aug 22;93(4):464-71.

17.

Platelet-derived endothelial cell growth factor/thymidine phosphorylase immunohistochemical expression in lymphoid tissue and lymphoid malignancies.

Doussis-Anagnostopoulou IA, Remadi S, Turley H, Gindre P, Comley M, Borisch B, Gatter KC.

Hum Pathol. 1997 Oct;28(10):1146-51.

PMID:
9343321
18.

nm23-H1 expression in non-Hodgkin and Hodgkin lymphomas.

Bircan S, Inamdar KV, Rassidakis GZ, Medeiros LJ.

Appl Immunohistochem Mol Morphol. 2008 May;16(3):207-14. doi: 10.1097/PAI.0b013e318156f1ab.

PMID:
18301251
19.

The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease.

Konjević G, Jurisić V, Banićevic B, Spuzić I.

Br J Haematol. 1999 Jan;104(1):144-51.

PMID:
10027727
20.

Knockdown of UbcH10 enhances the chemosensitivity of dual drug resistant breast cancer cells to epirubicin and docetaxel.

Wang C, Pan YH, Shan M, Xu M, Bao JL, Zhao LM.

Int J Mol Sci. 2015 Mar 2;16(3):4698-712. doi: 10.3390/ijms16034698.

Items per page

Supplemental Content

Write to the Help Desk